Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.

Family Heart Foundation Launches AI Model for Early Cardiovascular Disease Detection

What You Should Know: – The Family Heart Foundation, a leader in cardiovascular research and advocacy, has unveiled an “FIND Lp(a)” a machine learning model

September 20, 2024

Novel nasal spray shows promise in preventing respiratory infections

New research published in Advanced Materials reports a novel nasal spray for preventing respiratory infections.

September 25, 2024

Redi Health Secures $14M to Transform Patient Support Programs

What You Should Know: – Redi Health, an innovator in digital health solutions, announced today the successful closing of a $14 million Series B funding

February 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.